AIxCrypto Holdings, Inc. (AIXC) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
No case yet. It builds on the next filing, report or 13F period.
AIxCrypto Holdings, Inc. has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 6199, Finance Services, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
11 managers report a position worth $672,982 between them, and 3 of them hold 80% of it.
High 1.17 at 3:15 pm ET, low 0.99 at 10:00 am ET.
AIxCrypto Holdings, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Finance Services
AIXC (AIxCrypto Holdings, Inc.) has 1 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.